Prismaflex st150 set has been temporarily approved for use in the us under emergency use authorization eua200704 to deliver crrt to treat patients in an acute care environment during the covid-19 pandemic.The device was discarded and the lot number is unknown; therefore, a device analysis could not be completed, however, based on the information receive the cause of the reported condition is user related.The function of dialysis is to filter blood.As per prismaflex st150 set instruction for use (ifu): ¿since drugs can pass through the membrane of the filter, the dosage of associated drug treatments must be adjusted for patients on continuous renal replacement therapy¿.This is a known effect of the device that would have been mitigated by appropriate dosage adjustment of ambisome by the clinician.Should additional relevant information become available, a supplemental report will be submitted.
|
It was reported that a patient experienced ¿ineffectiveness of treatment following the establishment of an extra-renal purification following the appearance of an acute kidney injury" and invasive candidiasis.The patient was performing continuous veno-venous hemodiafiltration (cvvhdf) using a prismaflex st150.The patient was transferred to the intensive care unit and treated with axepim 2g x 2/d, flagyl 500 mg x3/d, ambisome (5 then 3 mg/kg/d (210 mg/d) continuously and uninterrupted for 67 days), lasix, morphine titration and cortancyl 80 mg/d.The patient was intubated and was provided hemodynamic support with noradrenaline and dobutamine.It was not reported if the patient recovered om the invasive candidiasis event.No additional information were provided.
|